Black Diamond Therapeutics, INC Form 4 insider transactions

Director Ali Behbahani of Black Diamond Therapeutics, Inc. acquired stock options for 40,000 shares, with vesting contingent on continued service.

Director Samarth Kulkarni of Black Diamond Therapeutics, Inc. acquired 40,000 stock options with an exercise price of $1.71.

Garry E. Menzel, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026.

Raman Prakash, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026, with an exercise price of $1.71.

Kapil Dhingra, a Director at Black Diamond Therapeutics, acquired 40,000 stock options with an exercise price of $1.71.

Shannon Campbell, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026.

Black Diamond Therapeutics director Ali Behbahani acquired 6,919 shares of common stock at $2.15 per share, opting for equity in lieu of cash compensation.

Black Diamond Therapeutics Director Prakash Raman acquired 6,105 shares of common stock in lieu of cash compensation for his annual services.

Black Diamond Therapeutics' Senior VP of Finance, Erika Jones, was granted 200,000 stock options with an exercise price of $2.57, vesting over four years.

Brent Hatzis-Schoch, Chief Operating Officer and General Counsel of Black Diamond Therapeutics, Inc., was granted 250,000 stock options at an exercise price of $2.57 per share.

Black Diamond Therapeutics' Chief Scientific Officer, Elizabeth Buck, was granted 250,000 stock options with a $2.57 exercise price, vesting over four years.

Black Diamond Therapeutics' Chief Medical Officer, Sergey Yurasov, was granted 250,000 stock options with an exercise price of $2.57, vesting over four years.

Black Diamond Therapeutics' President and CEO, Mark A. Velleca, was granted 600,000 stock options with an exercise price of $2.57, vesting over four years.

Black Diamond Therapeutics director Ali Behbahani acquired 5,208 shares of common stock as part of his compensation plan, electing equity over cash.

Black Diamond Therapeutics Director Prakash Raman acquired 4,665 shares of common stock in lieu of cash compensation for his annual services.

Black Diamond Therapeutics director Ali Behbahani acquired 4,291 shares of common stock in lieu of cash compensation.

Black Diamond Therapeutics Director Prakash Raman acquired 3,843 shares of common stock at $3.35 each, electing equity over cash compensation for his annual services.

Black Diamond Therapeutics, Inc. Director Ali Behbahani acquired 6,170 shares of common stock in lieu of cash compensation, increasing his beneficial ownership.

Prakash Raman, a Director at Black Diamond Therapeutics, Inc. (BDTX), acquired 5,526 shares of common stock by electing to receive equity in lieu of cash compensation for his annual services.

Ali Behbahani, a Director at Black Diamond Therapeutics, Inc., was granted stock options to purchase 30,550 shares of common stock at an exercise price of $2.43 per share.

Black Diamond Therapeutics, Inc. Director Garry E Menzel was granted 30,550 stock options with an exercise price of $2.43, vesting by June 2026 or the next annual meeting.

Black Diamond Therapeutics Director Prakash Raman was granted 30,550 stock options with an exercise price of $2.43, vesting over approximately one year.

Black Diamond Therapeutics, Inc. Director Shannon Campbell was granted 30,550 stock options with an exercise price of $2.43, vesting upon specific conditions.

Black Diamond Therapeutics, Inc. Director Kapil Dhingra was granted 30,550 stock options with an exercise price of $2.43, vesting fully by June 12, 2026, or the next annual meeting.

Black Diamond Therapeutics Director Samarth Kulkarni was granted 30,550 stock options with an exercise price of $2.43, vesting by June 2026 or the next annual meeting.

Director Ali Behbahani acquired 7,646 shares of Black Diamond Therapeutics common stock in lieu of cash compensation for annual services as a non-employee director.

Director Prakash Raman acquires 6,848 shares of Black Diamond Therapeutics (BDTX) common stock at $1.88 per share in lieu of cash compensation.

Biotech Growth N.V., a 10% owner of Black Diamond Therapeutics, Inc., disposed of 5,784,292 shares of common stock on March 19, 2025.

Mark A. Velleca, CEO of Black Diamond Therapeutics, was granted stock options and restricted stock units (RSUs) on January 30, 2025, according to a Form 4 filing with the SEC.

Sergey Yurasov, Chief Medical Officer of Black Diamond Therapeutics, was granted stock options and restricted stock units (RSUs) on January 30, 2025, according to a recent SEC filing.